-
New anti-inflammatory drugs! Baishi Meishi Guibao oral TYK2 inhibitor deucravacitinib treatment plaque psoriasis 2 phase 3 clinical success!
Time of Update: 2021-02-13
February 06, 2021 // -- BMS recently announced that the evaluation of the new anti-inflammatory drug deucravacitinib (BMS-986165) for the treatment of moderate to severe plaque psoriasis key Phase 3 study POETYK PSO-2 has reached a common primary endpoint and several key secondary endpoints.
-
JAHA: China's kaifeng study - prediabetes to restore blood sugar levels on the protection of cardiovascular and cerebrovascular effect
Time of Update: 2021-02-13
recently, a study published in the Journal of the American Heart Association (JAHA) showed that people with prediabetes regain normal blood sugar, which can improve the risk of CVDs and all-cause death such as heart attack and stroke.
-
"The father of lupus in China" Chen Shunle died, a lifetime wish patients like beautiful butterfly dance
Time of Update: 2021-02-13
Professor Chen Shunle, born in February 1932, is the founder of the rheumatology department of Renji Hospital, affiliated with Shanghai Jiaoxuan University School of Medicine, and the Shanghai Institute of Rheumatology, which has presided over the establishment of China's largest genetic database of the core family of lupus, and the creation of a combination of immunosuppressants to improve efficacy while reducing side effects.
-
New drug for psoriasis! The Lancet back-to-back IL-17A/F inhibitor bimekizumab study: Better than Stelara!
Time of Update: 2021-02-13
February 06, 2021 // -- UCB recently announced that the results of two Phase 3 studies (BE VIVID, BE READY) evaluating the treatment of adult patients with moderate to severe plaque psoriasis with the new anti-inflammatory drug bimekizumab have been published in the international authoritative medical journal The Lancet.
-
The multidisciplinary statement calls for: Diabetics don't forget to screen for liver disease!
Time of Update: 2021-02-13
There is growing evidence that the prevalence of fatty liver disease, advanced fibrosis and cirrhosis is alarmingly high in patients with type 2 diabetes (T2DM).
-
Allergy: new immunotherapy to treat allergic reactions in cats
Time of Update: 2021-02-11
(Photo source: www.pixabay.com) "We're trying to explore new ways to increase AIT anti-inflammatory activity with CpG, a known immunomodulator, but at a safer dose than previously used for this type of therapy," explains allergy and immunologist Dr. Cathy Léonard.
-
Nat Commun: The coronavirus can spread to humans
Time of Update: 2021-02-11
study publish.com ed in Nature Communications, scientists compared SARS-CoV-2, the most similar bat coronavirus raTG13 and the structure of the coronavirus isolated from a roller coaster, in a study published in Nature Communications.
-
Nat Commun: Anti-cancer drugs help treat severely ill patients with COVID19
Time of Update: 2021-02-11
February 7, 2021 /--- According to a small clinical study conducted in Italy and China between February and April 2020 by researchers at the Karolinska Institute in Sweden, the use of the anti-cancer drug beva monotherapy for severe COVID-19 patients can reduce mortality and speed up recovery.
-
Nat Commun: How are blood vessels and lymph nodes separated during development?
Time of Update: 2021-02-11
addition, even in mice with normal blood and lymphatic tube separation, the absence of the Flcn gene induced in endothoste cells can lead to an abnormal match between the two blood vessels.
-
Nature: Chronic SARS-CoV-2 infections can trigger mutations
Time of Update: 2021-02-11
FEBRUARY 7, 2021 /--- -- A team led by Cambridge researchers recently published an article in the journal Nature on how they observed the SARS-CoV-2 mutation in immunodeficiated patients receiving restorative plasma therapy.
-
Will SARS-CoV-2, everyone's "talking color change", be the next big pop "Terminator"?
Time of Update: 2021-02-10
And if the nasal virus is first inoculated in in-body cultured respiratory tissue and then IAVI is inoculated, the antiviral interferon response, which played an important role in the host's resistance to viral infection, will be activated in advance, thus achieving the effect of suppressing IAVI infection and reducing the replication of the virus.
-
Nat Commun: Identification of new gene constellations associated with systemic lupus erythematosus and genetic heterogeneity analysis of ancestral groups
Time of Update: 2021-02-10
a total of aggregate statistics from different ancestral groups analyzed by the Multigene Risk Score (PRS), the above analysis helps to reveal the genetic basis for SLE differences in ancestral groups.
-
UCB published the latest data in Lancet on the treatment of plaque-like psoriasis
Time of Update: 2021-02-10
The Lancet journal published two Studies on the treatment of moderate to severe plaque-like psoriasis phase III of the drug bimekizumab.
FDA and EMA accepted the company's Application for Biological Agent Licensing (BLA) and Market Licensing (MAA) for bimekizumab, a moderate to severe plaque-like psoriasis, respectively, in September 2020.
-
How to treat systemic sclerosis? The candidate drug GS248 may provide clinical benefits
Time of Update: 2021-02-03
in the first stage, this can lead to reduced blood flow to the fingers and toes, which in turn causes pain and impairs fine motor function.
Phase I study showed that GS-248 has good pharmacodynamic properties, supports daily dosing, and has strong and long-lasting anti-inflammatory properties (PGE2 reduction) and vascular protection (increased prostocycline).
-
Science Advances: Duke scientists find that exercise can really prevent being "bullyed" by inflammation!
Time of Update: 2021-02-03
Though previous studies in humans and animals have shown that exercise can generally help mitigate the effects of inflammation, it is difficult to distinguish between what role muscle cells themselves play in it and how they interact with specific disease-caused molecules such as interferon-γ.
-
Nature: In the face of the new coronavirus mutation, the body's immune system is constantly coping with evolution!
Time of Update: 2021-02-03
After 2 6.2 months, although the body fluid and active antibodies significantly decreased, but the memory B cells in the evolution of somogenic cell super-mutation, expressed with enhanced effectiveness and resistance to RBD mutation antibodies, solibo immunity has been developing.
-
Scientists used a non-toxic Botox drug delivery platform to treat Botox poisoning
Time of Update: 2021-02-02
Because botulinum toxins can efficiently target motor neurons and nerve endings, general therapeutic drugs cannot enter neurons, so once paralysis occurs, you can only wait for these toxins to slowly disappear, there is no better treatment to reverse the process.
-
Science Sub-Journal Interpretation! It is revealed that preterm delivery of the mother is related to the migration of fetal immune cells to the mother, and the use of exosome delivery NF-kB inhibitors has the potential to reduce premature birth
Time of Update: 2021-01-29
Once there was evidence of fetal cell migration, the researchers then used the mouse model to determine whether bioengineered exosomes could deliver a special anti-inflammatory drug---NF-kB inhibitor, SR I-B alpha--- from the mother's blood to the fetus.
-
JAK inhibitor safety issues! Pfizer Xeljanz Therapeutic Rheumatoid Arthritis Post-Market Study: Less Safe Than TNF Inhibitors!
Time of Update: 2021-01-29
the study's common primary endpoint was the non-poor effectiveness of Xeljanz compared to TNFi in terms of major adverse cardiovascular events (MACEs) and malignant tumors (excluding non-melanoma skin cancer (NMSC).
-
Science: New research suggests that COVID-19 is likely to eventually turn into a mildly symptomatic epidemic
Time of Update: 2021-01-27
"In the vast majority of cases, the human coronavirus (HCoV) causes only the common cold, which means upper respiratory tract infections," said Jennie Lavine, a postdoctoral researcher in the Department of Biology at Emory University in the United States and author of the paper.